Osteoporos Int. 2015 Dec;26(12):2773-83. doi: 10.1007/s00198-015-3234-7. Epub 2015 Jul 23.

CONCLUSIONS: Denosumab treatment for up to 8 years was associated with persistent reductions of BTMs, continued BMD gains, low fracture incidence, and a consistent safety profile.

Autor: Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG.

Leave a Reply

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

  • 1 × 4 =